Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KYNU | Q16719 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | CTSK | P43235 | 10/20 | 0.54 |
| ▸ | TACR1 | P25103 | 1/20 | 0.51 |
| ▸ | CTSS | P25774 | 4/20 | 0.51 |
| ▸ | CTSL | P07711 | 3/20 | 0.51 |
| ▸ | CTSB | P07858 | 2/20 | 0.51 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28162782 | 1.00 | KYNU (0.60) | KYNUALDH1A1ALOX15CTSKTACR1 | |
| SCHEMBL21837385 | 0.94 | KYNU (0.58) | KYNUALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL21837386 | 0.94 | KYNU (0.58) | KYNUALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL527104 | 0.91 | CTSK (0.64) | KYNUALDH1A1ALOX15CTSKTACR1 | |
| SCHEMBL4387860 | 0.91 | CTSK (0.64) | KYNUALDH1A1ALOX15CTSKTACR1 | |
| SCHEMBL527103 | 0.91 | CTSK (0.64) | KYNUALDH1A1ALOX15CTSKTACR1 | |
| SCHEMBL1832552 | 0.90 | KYNU (0.57) | KYNUALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL1837491 | 0.90 | KYNU (0.57) | KYNUALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL16351361 | 0.89 | KYNU (0.62) | KYNUALDH1A1ALOX15CTSKTACR1 | |
| SCHEMBL31604948 | 0.89 | KYNU (0.56) | KYNUALDH1A1ALOX15CTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9839641-B2 | Compounds and methods for treating bacterial infections | ENTASIS THERAPEUTICS LIMITED (GB) | 2017-12-12 | — | — | US | disclosed |
| US-9839641-B2 | Compounds and methods for treating bacterial infections | ENTASIS THERAPEUTICS LIMITED (GB) | 2017-12-12 | — | — | US | disclosed |
| US-9839641-B2 | Compounds and methods for treating bacterial infections | ENTASIS THERAPEUTICS LIMITED (GB) | 2017-12-12 | — | — | US | disclosed |
| CN-105229012-B | Compounds and methods for for treating bacterium infection | 恩塔西斯治疗有限公司 | 2017-07-18 | — | — | CN | disclosed |
| US-20170128458-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | ENTASIS THERAPEUTICS INC. | 2017-05-11 | — | — | US | disclosed |
| US-20170128458-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | ENTASIS THERAPEUTICS INC. | 2017-05-11 | — | — | US | disclosed |
| US-20170128458-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | ENTASIS THERAPEUTICS INC. | 2017-05-11 | — | — | US | disclosed |
| US-9540394-B2 | Compounds and methods for treating bacterial infections | ENTASIS THERAPEUTICS LIMITED (GB) | 2017-01-10 | — | — | US | disclosed |
| US-20160130281-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | ENTASIS THERAPEUTICS INC. | 2016-05-12 | — | — | US | disclosed |
| US-20160130281-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | ENTASIS THERAPEUTICS INC. | 2016-05-12 | — | — | US | disclosed |
| US-8889671-B2 | Compounds and methods for treating bacterial infections | ASTRAZENECA AB (SE) | 2014-11-18 | — | — | US | disclosed |
| US-8889671-B2 | Compounds and methods for treating bacterial infections | ASTRAZENECA AB (SE) | 2014-11-18 | — | — | US | disclosed |
| US-8889671-B2 | Compounds and methods for treating bacterial infections | ASTRAZENECA AB (SE) | 2014-11-18 | — | — | US | disclosed |
| WO-2014114929-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2014-07-31 | — | — | WO | disclosed |
| US-20140206677-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2014-07-24 | — | — | US | disclosed |
| US-20140206677-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2014-07-24 | — | — | US | disclosed |
| US-20140206677-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2014-07-24 | — | — | US | disclosed |
| US-20070249670-A1 | Glycogen Phosphorylase Inhibitor Compounds and Pharmaceutical Compositions Thereof | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-25 | — | — | US | disclosed |
| EP-1812383-A1 | GLYCOGEN PHOSPHORYLASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | Smithkline Beecham Corporation (US) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006052722-A1 | GLYCOGEN PHOSPHORYLASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206677-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | NISCH, ELANE, ALPI | KYNU 3399/4885ALDH1A1 597/4885ALOX15 454/4885 |
| US-20070249670-A1 | Glycogen Phosphorylase Inhibitor Compounds and Pharmaceutical Compositions Thereof | PYGM, PYGL, GYS1 | KYNU 4372/4885ALDH1A1 2212/4885ALOX15 2047/4885 |
| US-20160130281-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | NISCH, ELANE, ALPI | KYNU 3399/4885ALDH1A1 597/4885ALOX15 454/4885 |
| US-20170128458-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | NISCH, ELANE, ALPI | KYNU 3399/4885ALDH1A1 597/4885ALOX15 454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.